Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Oslo - Delayed Quote • NOK Photocure ASA (PHO.OL) Follow Add holdings 56.50 +2.30 +(4.24%) At close: April 25 at 4:25:12 PM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for PHO.OL 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: PHO.OL View More All News Press Releases SEC Filings Photocure appoints Jane Healy as Vice President and General Manager EMEA Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence Photocure ASA: Results for the fourth quarter of 2024 News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025 Photocure ASA: Results for the third quarter of 2024 Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting Photocure establishes Named Patient Program to provide access to Hexvix in South Africa Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference Photocure ASA: Results for the second quarter of 2024 Related Tickers 1061.HK ESSEX BIO-TECH 4.380 -0.45% 2633.HK Jacobson Pharma Corporation Limited 1.230 -1.60% 2161.HK JBM (Healthcare) Limited 2.260 +2.26% CRNO-B.ST Cereno Scientific AB (publ) 8.00 +0.38% TEVA Teva Pharmaceutical Industries Limited 14.87 +1.02%